A remarkable medical achievement was quietly reported in the New England Journal of Medicine on 9 December 1982. Ley and his co-workers (1982) treated 3 patients with homozygous beta-thalassaemia and 2 patients with homozygous sickle cell disease with a single drug, 5 azacytidine. For the duration of the regimens they successfully and favourably altered the molecular constitution of the haemoglobin species in these 5 patients. This response to a single therapeutic agent is noteworthy because sickle cell disease and betathalassaemia have distinctly disparate molecular mechanisms. In the course of their treatments, these workers activated the operon for the gammaglobin of haemoglobin F, a genome prominently active during the second trimester of intrauterine life but markedly muted thereafter. The epoch of gene-switching for the therapeutic management of genetic diseases has arrived.
Before we can appreciate the magnificence of this therapeutic advance and its clinical thrust, an understanding of the genetic control of the biosynthesis of the haemoglobin molecule during intrauterine life is essential.
A single haemoglobin molecule is composed of about 10000 atoms arranged in 2 sets of dyads, 2 alpha-globin chains and 2 beta-globin chains. These sets are in a quaternery structure such that each globin chain has in its hydrophobic 'pocket' a haem group, each of which will stoichiometrically and reversibly bind one molecule of oxygen. Thus, each tetramer of haemoglobin, when fully loaded with oxygen, undergoing a conformational change, will transport 8 atoms of oxygen. This oxygen transport must begin early in intrauterine life. Furthermore, the embryonic and fetal haemoglobins must successfully compete for oxygen with maternal haemoglobin A. This condition is achieved 'by the developing embryo through the synthesis of a variety of haemoglobins, all of which have a higher affinity for molecular oxygen than does the maternal tetramer of haemoglobin A. This functional advantage is mediated by haemoglobins structurally analogous in part to haemoglobins of fish, recapitulating our phylogeny, and in part due to the reduced ability of such haemoglobins to bind 2, 3 DPG. These features shift the allosteric equilibrium between the two principal sterostructures of haemoglobin to the 'left' or 'R' conformation which binds and transports oxygen, in contrast to the 'T' conformation which is the oxygen-free form of haemoglobin.
In the first trimester of intrauterine life there is a bewildering array of globin chains, synthesized in a synchronized fashion, designated as alpha, beta, gamma, epsilon, and zeta ( Figure 1 ). In order for haemoglobin to function as a vehicle for the transport and release of oxygen, it must be composed of 2 dissimilar dyads, i.e., alpha2 beta2= haemoglobin A. A homozygous tetramer of haemoglobin such as haemoglobin Bart's, i.e. gamma4, acquires the 'R' molecular conformation and avidly binds oxygen, never to release it. In the first trimester the zeta-globin is the analogue of the alpha-globin and both coexist for a time almost simultaneously. But unlike the zeta-globin, the alpha-globin persists throughout life. Similarly the epsilonand gamma-globins are analogous to the beta-globin. The latter persists into adult life. Hence, in the first trimester of intrauterine life, the prevalent molecular species of high oxygen affinity haemoglobins are: haemoglobin Portland (zeta2 gamma2); haemoglobin Gower 1 (zeta2 epsilon2); haemoglobin Gower 2 (alpha2 epsilon2).
In the second trimester haemoglobin F (alpha2 gamma2) is predominant. By the third trimester haemoglobin A2 (alpha2 delta2) and haemoglobin A (alpha2 beta2) are in evidence. As the first trimester haemoglobins rise to peak levels of concentration, the embryo by chemically mediated signals inhibits the structural genes for zeta-and epsilonglobins and simultaneously activates the structural genes for alpha-and gamma-globins to form haemoglobin F through the second trimester and into the first 4 to 6 months of postnatal life. Fetal haemoglobin also has a high affinity for oxygen. In the third trimester, the structural gene for gamma-globin is gradually inhibited, while in a synchronized, reciprocal fashion the beta-globin structural gene is activated and this gene product, betaglobin, is increased in concentration to couple with available alpha-globins to form haemoglobin A. This complex interplay of gene activators and inhibitors, of multiple genes, with the rise and fall of gene products, and the several molecular species of haemoglobin, all appear to be required by the embryo to negotiate intrauterine life.
Clinical insights
There are two major classes of haemoglobinopathies. Qualitative haemoglobinopathies have structural alterations in the amino acid sequences of a given globin chain at variance from the normal prototype. In sickle cell disease the beta-globin chain is flawed due to the substitution of valine for glutamic acid in the number 6 position. Quantitative haemoglobinopathies are characterized either by a total absence of a given chain, i.e. beta' thalassaemia, or by the presence of significantly reduced quantities of a normally structured globin, i.e. beta+ thalassaemia.
At the end of the first trimester, when haemoglobin Portland, Gower 1 and Gower 2 are in descendancy as their structural genes are inhibited, they are replaced by the ascendancy of haemoglobin F. In molecular terms the zeta-and epsilon-globins are being replaced by alpha-and gamma-globins. Let us consider what would happen if the zeta-and epsilonglobins fell in the usual manner to zero levels of concentration at the end of the first trimester and were associated coincidentally with a failure of the gamma structural gene to produce gamma-globin. There would follow a progressive and lethal intrauterine anaemia causing abortion. Since such a gamma-globin abnormality would be a quantitative deficiency, this intrauterine disorder could accurately be characterized as a 'zeta' or 'epsilonthalassaemia'. Such a theory could adequately explain the puzzling, peak incidence of abortions which occur at the end of the first trimester in the absence of placental or hormonal abnormalities (Nalbandian et al. 1971) . Thus the functional importance of gamma-globin is evident.
Response of maternal genes to fetal signals
Another clinical insight of considerable relevance in management of sickle cell anaemia and thalassaemia has been reported by Pembrey & Weatherall (1971) . These investigators noted a distinct increase in haemoglobin F levels in the blood of pregnant women in their second trimester. This maternal response is the result of a chemical signal elaborated by the fetus as its rising levels of haemoglobin F replace antecedent molecular species. The significant inferences are: (1) The fetal structural gene for gamma-globin responds to a water-soluble metabolite which can pass through the placenta into the maternal blood, functionally unaltered.
(2) The maternal structural gene for gamma production may be reactivated sufficiently to produce a significant quantity of the gene product, gamma-globin.
(3) The activity of the maternal genome for gamma-globin reflects the fall in the fetal gamma-globin concentration as the third trimester of pregnancy is entered. Such information is directly applicable to the medical management of sickle cell and thalassaemic disorders.
Hereditary persistent fetal haemoglobin (HPFH)
In normal circumstances at the end of the second trimester the production of gamma-globin and beta-globin are in a quantitative, inversely proportional relationship. The gamma-globin operon is gradually repressed and the beta-globin operon is activated; haemoglobin F is thus gradually replaced by haemoglobin A through the third trimester of pregnancy and the first 4 to 6 months of postnatal life. However, if the inversely synchronized genetic mechanism fails, the fetus would survive birth and the postnatal period with only haemoglobin F.
Haemoglobin F is compatible with an asymptomatic clinical course and full life span; variants of this condition are referred to as hereditary persistent fetal haemoglobin (HPFH). Hence, if a qualitative haemoglobinopathy such as sickle cell disease, a beta-chain abnormality, or a quantitative haemoglobinopathy such as beta-thalassaemia, with total absence of the beta-globin chain, could be converted pharmacologically into a state similar to HPFH by periodic activation of gamma-globin operon, these two dreaded and lethal diseases could be converted into asymptomatic states. (Other mechanisms for HPFH occur).
Medical therapy of sickle cell disease and homozygous beta-thalassaemia Figure 1 demonstrates that symptomatic patients with sickle cell disease or homozygous beta-thalassaemia may be converted into asymptomatic states by a single chemotherapeutic agent, although the molecular mechanisms of these two diseases are different (Nalbandian 1973 , 1982 , Benz & Forget 1974 , Stamatoyannopoulos & Nienhuis 1979 . Sickle cell disease and beta-thalassaemia afflict millions throughout the world. They involve qualitative and quantitative abnormalities of beta-globin construction or production. Each is mediated by molecular mechanisms that are unrelated. Molecular medicine and genetics offer the victims of both these diseases the possibility of escape from their afflictions by activation of the structural gene for gamma-globin production.
As may be expected with the advent of a new therapeutic epoch in medicine, both kudos (Orkin 1983 , Benz 1982 and criticism (Lancet 1983 , Clegg et al. 1983 ) are encountered simultaneously. A fair body of recently published work supports but does not yet explain the mechanism of action of 5-azacytidine, i.e. demethylation of DNA versus perturbation of marrow progenitors (De Simone et al. 1978 , 1982 , Jones & Taylor 1980 , van der Ploeg & Flavell 1980 , Ehrlich & Wang 1981 , Groudine et al. 1981 , Clough et al. 1982 , Felsenfeld & McGhee 1982 ). An independent group (Charache et al. 1982) from Johns Hopkins Medical School has confirmed the findings of Ley et al. (1982) .
The pioneering work of Ley et al. (1982 Ley et al. ( , 1983 has demonstrated that therapy with 5azacytidine temporarily increases the concentrations of functional haemoglobin F in patients with beta-thalassaemia and sickle cell disease. This successful 'gene switching' for therapeutic purposes is worthy of every accolade medicine has to offer, and will stimulate numerous penetrating studies. The ultimate therapeutic goal for the victims of these fatal diseasesan effective form of oral therapymay be within our grasp.
